Board Change • Jul 03
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Board Member Robert Molander was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Jun 30
Biosergen AB (Publ) Appoints Mattias Klintemar as Chairman of the Board Biosergen AB (publ) announced at the AGM held on June 30, 2026, approved Mattias Klintemar was appointed Chairman of the Board. Announcement • Jun 28
Flerie AB (publ) (OM:FLERIE) agreed to acquire Biosergen AB (publ) (OM:BIOSGN) from Östersjöstiftelsen, Ribbskottet AB and others for SEK 1.5 million. Flerie AB (publ) (OM:FLERIE) agreed to acquire Biosergen AB (publ) (OM:BIOSGN) from Östersjöstiftelsen, Ribbskottet AB and others for SEK 1.5 million on June 25, 2026. Accordingly, new ordinary shares in Flerie will be issued to Biosergen’s shareholders in proportion to their existing shareholdings in Biosergen at an exchange ratio of 31:1. Flerie has been ascribed a value of SEK 20.29 per share and Biosergen has been ascribed a value of approximately SEK 0.67 per share. The Merger Consideration for Biosergen’s shareholders, comprising newly issued ordinary shares in Flerie, values Biosergen at approximately SEK 54.7 million, representing a premium of approximately 33% to Biosergen’s post-money value in the Rights Issue. The Merger requires, among other things, approvals at the Extraordinary General Meetings of the Companies and the completion of the Rights Issue, which will result in Biosergen receiving issue proceeds of at least approximately SEK 39.9 million before deduction of issue costs, at a subscription price of SEK 0.50 per share and comprising up to 79,839,888 new shares in Biosergen. Following the completion of the Merger, Biosergen’s operations will be contributed to a new subsidiary of Flerie’s wholly owned subsidiary, Flerie Invest AB.
The transaction is subject to approval by regulatory board / committee, approval of offer by target shareholders and approval of offer by acquirer shareholders. Registration of the Merger is expected to take place during the last quarter of 2026. The Merger is expected to have a very limited impact on Flerie’s performance and financial position, both in the short term and over a longer period.
Setterwalls Advokatbyrå Ab acted as legal advisor for Flerie AB (publ). Hagberg & Aneborn Fondkommission AB acted as issuing agent for Flerie AB (publ). BAHR Advokatbyrå AB acted as legal advisor for Biosergen AB (publ). 
